BBI Life Sciences
Shanghai
About BBI Life Sciences
BBI Life Sciences Corporation is one of the leading providers with the widest portfolio coverage in the life sciences research products and services industry in China. Their comprehensive product and service portfolio for life sciences research has an extensive range of applications, including (i) DNA synthesis products, (ii) genetic engineering services, (iii) life sciences research consumables; and (iv) protein and antibody related products and services. Their customers include colleges and universities, research institutes, hospitals, pharmaceutical and biotech companies, government testing and diagnostic centres, as well as distribution companies in China and overseas. Moreover, their Sangon and BBI brands have become highly recognisable in the market based on product and service quality, price competitiveness, and express delivery services. In terms of revenue in 2013, they are the largest provider of DNA synthesis products in China, and also ranked first among oligonucleotide synthesis product providers as a sub-segment of DNA synthesis products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $10K – $50K
- Total funding: $10.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2015)
- Ticker: hkg:1035
- Website: bbi-lifesciences.com
- Phone: +86218008201016
Industries & Categories
Biotechnology, Delivery Service, Health Care, Life Science
Canonical: https://fsome.com/organization/bbi-life-sciences-3106785 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.